PAHCPHIBRO ANIMAL HEALTH CORP
Pharmaceutical Preparations
- Revenue
- $1.5B
- 17% YoY
- Operating margin
- 12.8%
- 50% YoY
- EBITDA
- $246M
- 58% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- 1.1×
- $259M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashFired69% of net incomeCash flow under 80% of net income
- Dilutive SBCClear0% of revenueOver 10% of revenue
- Payouts exceed cash flowClear28% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear4% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $942M | $978M | $1.0B | $1.3B | $1.5B | 17% |
| Operating income | $79M | $72M | $53M | $110M | $194M | 76% |
| Net income | $49M | $33M | $2M | $48M | $100M | 107% |
| Operating cash flow | $32M | $13M | $88M | $80M | $69M | 14% |
| Capex | $37M | $52M | $41M | $38M | $59M | 54% |
| Stock-based comp | — | — | $475K | $717K | $2M | 123% |
| Dividends | $19M | $19M | $19M | $19M | $19M | 0.1% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2026 | $5M | $5M | 123 | 136 |
| FY2025 | $5M | $5M | 111 | 99 |
| FY2024 | $5M | $4M | 72 | 97 |
| FY2023 | $3M | $3M | 56 | 98 |
| FY2022 | $4M | $4M | 76 | 100 |